ASH2024注目テーマ⑦注目演題「#773」

高リスクくすぶり型MMへのダラツムマブ、
積極的経過観察よりMMへの進行を遅延 Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study (#773)

Meletios-Athanasios Dimopoulos（National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece）